Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway

Biochemical and Biophysical Research Communications

Volumn 437, Issue 4, 2013, Pages 557-564

  Ahn, Hee Jin ^a   Kim, Gwangil ^a   Park, Kyung Soon ^a  

^a CHA University   (South Korea)

Author keywords

5 FU; Breast cancer; Cancer stem cells; Ell3; ERK1 2; Proliferation

Indexed keywords

CD44V ANTIGEN; ELL3 TRANSCRIPTION ELONGATION FACTOR; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION ELONGATION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE G2 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; IN VIVO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

5-FU; BREAST CANCER; CANCER STEM CELLS; ELL3; ERK1/2; PROLIFERATION;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RETINAL DEHYDROGENASE; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ELONGATION FACTORS;

MURINAE;

EID: 84881548569     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.114     Document Type: Article

References (23)

1. Ng C.K., Pemberton H.N., Reis-Filho J.S. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther 2012, 12:1021-1032.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
3. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
4. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
5. Liu H., Patel M.R., Prescher J.A., Patsialou A., Qian D., Lin J., Wen S., Chang Y.F., Bachmann M.H., Shimono Y., Dalerba P., Adorno M., Lobo N., Bueno J., Dirbas F.M., Goswami S., Somlo G., Condeelis J., Contag C.H., Gambhir S.S., Clarke M.F. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 2010, 107:18115-18120.
6. van der Weyden L., Adams D.J. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007, 1776:58-85.
7. Pratilas C.A., Solit D.B. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010, 16:3329-3334.
8. Yim E.K., Siwko S., Lin S.Y. Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle 2009, 8:2360-2364.
9. Kandouz M., Haidara K., Zhao J., Brisson M.L., Batist G. The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. Cell Cycle 2010, 9:398-407.
10. Miller T., Williams K., Johnstone R.W., Shilatifard A. Identification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3. J Biol Chem 2000, 275:32052-32056.
11. Maki K., Mitani K., Yamagata T., Kurokawa M., Kanda Y., Yazaki Y., Hirai H. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia. Blood 1999, 93:3216-3224.
12. Lin C., Garruss A.S., Luo Z., Guo F., Shilatifard A. The RNA Pol II elongation factor Ell3 marks enhancers in ES cells and primes future gene activation. Cell 2013, 152:144-156.
13. Ahn H.J., Cha Y., Moon S.H., Jung J.E., Park K.S. Ell3 enhances differentiation of mouse embryonic stem cells by regulating epithelial-mesenchymal transition and apoptosis. PLoS One 2012, 7:e40293.
14. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992, 11:961-971.
15. Stacey D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003, 15:158-163.
16. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511.
17. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
18. Inoue A., Takahashi H., Harada H., Kohno S., Ohue S., Kobayashi K., Yano H., Tanaka J., Ohnishi T. Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. Int J Oncol 2010, 37:1121-1131.
19. Mebratu Y., Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?. Cell Cycle 2009, 8:1168-1175.
20. Jirmanova L., Afanassieff M., Gobert-Gosse S., Markossian S., Savatier P. Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene 2002, 21:5515-5528.
21. Han S., Sidell N., Roman J. Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett 2005, 219:71-81.
22. Chang C.J., Yang J.Y., Xia W., Chen C.T., Xie X., Chao C.H., Woodward W.A., Hsu J.M., Hortobagyi G.N., Hung M.C. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100.
23. Judd N.P., Winkler A.E., Murillo-Sauca O., Brotman J.J., Law J.H., Lewis J.S., Dunn G.P., Bui J.D., Sunwoo J.B., Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res 2012, 72:365-374.